Background: Therapeutic drug monitoring (TDM) could improve current TB treatment, but few studies have reported pharmacokinetic data together with MICs.
Introduction
The treatment of drug-susceptible TB is associated with a risk of poor adherence and subsequent development of drug resistance. 1, 2 Attempts to shorten treatment of drug-susceptible TB from the current 6 month regimen with fluoroquinolones have so far been unsuccessful. 3 The increase in MDR TB has further highlighted the need to improve TB treatment. Several studies, mainly from high endemic areas, have shown lower than recommended plasma drug concentrations for TB patients using standard dosages 1, [4] [5] [6] and low rifampicin concentrations (,8 mg/L) in particular. 1, [5] [6] [7] Normal ranges for peak plasma concentrations of first-line drugs are derived from early pharmacokinetic studies in healthy volunteers and TB patients on treatment and are overall poorly validated against clinical outcomes. 4, [7] [8] [9] [10] [11] [12] [13] [14] [15] Previous studies, using a wide range of sampling timepoints, have shown conflicting results regarding correlations between low drug concentrations and treatment outcomes. 5, 8, [16] [17] [18] [19] In a large clinical study in South Africa, a peak drug concentration of rifampicin !6.6 mg/L was predictive of 2 month sputum culture conversion using the current dosing. 1 Despite efforts, mainly based on animal and in vitro models, but also recently clinical studies, there are no accepted pharmacokinetic/pharmacodynamic (PK/PD) targets for TB treatment in humans. A hollow-fibre system (HFS) study suggested a ratio of free (ƒ) rifampicin C max /MIC !175 to attain sufficient bactericidal effect and to prevent acquired drug resistance. 20 In addition to C max /MIC, the area under the concentration versus time curve (AUC) in relation to the MIC has been reported both in animal models and humans to best describe the efficacy of first-line TB drugs. [21] [22] [23] In a murine aerosol infection model based on monotherapy, a ratio of 271 for rifampicin AUC/MIC was needed for a 1 log 10 cfu reduction. 22 Similarly, both HFS and animal models have shown that an isoniazid AUC/MIC .60 is needed to achieve significant efficacy. 23, 24 Clinical studies in patients with drug-susceptible TB have shown an increased bactericidal activity with higher doses of rifampicin ranging from 10 to 40 mg/kg during the first 14 days of therapy, 25, 26 which was later confirmed in a larger clinical trial, 27 suggesting that increased rifampicin dosing has promising potential to shorten treatment duration for drug-susceptible TB. 27 One possibility to enhance cure rates of TB is by individualizing treatment through therapeutic drug monitoring (TDM). The TDM strategy involves measuring plasma drug levels and making dose adjustments if the drug concentrations are out of range. Optimal TDM would benefit from PK/PD targets, which are yet to be established for TB. MIC determination provides information on the level of resistance and affects PK/PD. However, even though drug susceptibility testing methods based on Middlebrook media show similar MIC levels for first-line drugs, 28 systematic differences exist. Currently, WHO proposes BACTEC 960 MGIT as a reference method, 29 but there is a need for comparative studies to reach an evidence-based reference method for MIC determination for Mycobacterium tuberculosis.
Comprehensive data are scarce regarding TB drug exposure and individual MICs in low endemic settings. Therefore, our main objective was to explore plasma concentrations of isoniazid, rifampicin, pyrazinamide and ethambutol in TB patients, along with the corresponding individual MICs.
Patients and methods

Ethics
Patients were included prospectively after providing written informed consent between October 2012 and December 2014 at University Hospital Linköping, Sweden and Karolinska University Hospital Solna, Sweden. The study was approved by the regional ethics committee (DNR 2012/197-31) of Linköping University and registered at clinicaltrials.gov (NCT02042261).
Patients
Adult inpatients or outpatients starting treatment for active TB were eligible for inclusion. Exclusion criteria were MDR or XDR TB, ongoing treatment for infectious diseases other than HIV or patient inability to give informed consent. Definitions and treatment of pulmonary tuberculosis (PTB) and extrapulmonary tuberculosis (EPTB) were in accordance with WHO criteria. 2 Unless any resistance to first-line TB drugs was detected by routine drug susceptibility testing (described below), treatment according to WHO guidelines 2 for the first 2 months consisted of 5 (4-6) mg/kg isoniazid, 10 (8-12) mg/kg rifampicin, 25 (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) mg/kg pyrazinamide and 15 (15) (16) (17) (18) (19) (20) mg/kg ethambutol, followed by a 4 month continuation phase including only isoniazid and rifampicin. No fixed drug combination tablets were used and the same drug formulation was given to all patients. All patients were instructed to refrain from alcohol during TB treatment and to take rifampicin and isoniazid while fasting. At one of the study sites, rifampicin and isoniazid were ingested during fasting while pyrazinamide and ethambutol were taken with food 1-2 h later (n " 21/31). Treatment outcome was recorded according to WHO criteria. 30 Registration of TB relapse was done within 1 year after the end of TB treatment by reviewing clinical follow-up data in medical records and the national TB database at the Public Health Agency of Sweden.
Collection of baseline data and clinical symptoms included in TBscore II
Medical records were reviewed for basic demographic data, medical history and details of current TB disease (Table 1) . TBscore II was developed and validated in sub-Saharan Africa 31 and has been used as a surrogate marker for disease severity of TB. TBscore II was calculated for study patients based on the following variables: cough, dyspnoea, chest pain, anaemia, BMI and mid upper arm circumference. The score is graded from 0 to 8 points and the points-based definitions of severity classes are: ,2 (I), 2-3 (II), 4-7 (III) and .7 (IV).
Sputum sample collection, drug susceptibility testing and MIC determination
Morning sputum samples during fasting were obtained from PTB patients at baseline and after 2 months of treatment. MIC determination used for PK/PD analysis was performed in BACTEC MGIT 960 (Becton Dickinson, Lakes, NJ, USA) as previously described by using serial 2-fold dilutions of antibiotics. 28 For comparison, the newly developed Sensititre TM MYCOTB MIC plate (Thermo Fisher, Waltham, MA, USA) was used. The M. tuberculosis H37Rv strain (ATCC 27294) was included as an internal control. In MGIT, the MIC was defined as the lowest antibiotic concentration with less growth compared with the 1:100 diluted controls (for pyrazinamide 1:10 diluted controls), whereas in the MYCOTB plate, the MIC of a drug was considered the lowest concentration able to inhibit visible growth. To substantiate the MIC results, an analysis of established resistance mutations by WGS was included for first-line drugs (see Table S1 , available as Supplementary data at JAC Online). WHO-based critical concentrations for rifampicin, isoniazid, pyrazinamide and ethambutol were used for routine susceptibility testing of isolates in BACTEC MGIT 960 (1, 0.1, 100 and 5 mg/L, respectively).
Determination of first-line TB drug concentrations
For drug concentration analysis, 10 mL of blood was collected in the morning after an overnight fast at pre-dose and at 2, 4 and 6 h after observed drug intake 2 weeks after treatment initiation and repeated pre-dose and at 2 h at weeks 4 and 12. The plasma was separated and transported using an unbroken cold chain and stored at #70 C until analysis. The study was primarily designed to measure drug levels of all first-line drugs at 0, 2, 4 and 6 h at week 2. Additionally, the individual fluctuations of isoniazid and rifampicin levels during treatment were assessed by including repeated sampling at week 4 and week 12. Ingestion of pyrazinamide and Plasma concentrations of first-line anti-TB drugs versus MICs JAC ethambutol was delayed for 1-2 h compared with rifampicin and isoniazid at one of the study sites, so the measured drug concentrations of pyrazinamide and ethambutol were sampled 1-2 h before dose intake and 0-1, 2-3 and 4-5 h post-dose (illustrated in Figure S1c and d). Sample preparation for isoniazid and acetyl isoniazid was based on ultrafiltration at room temperature with a filter cut-off at 10000 Da, followed by acetylation, resulting in quantification of unbound concentrations. The analysis was performed by LC coupled to a UV detector (LC-UV; Agilent 1100 HLPC system, Santa Clara, CA, USA) with separation on a reversed phase column (Zorbax SB-C18, 3 lm, 75%4.6 mm, Agilent). For rifampicin, pyrazinamide and ethambutol, samples were prepared by organic solvent protein precipitation and analysed with an LC-MS system (Agilent 1200, Santa Clara, CA, USA) equipped with a reversed phase column (Kinetex 2.6 lm, C18 100 A, 50%2.1 mm, Phenomenex, Torrance, CA, USA). This resulted in quantification of total concentration for rifampicin, pyrazinamide and ethambutol. All patient samples were analysed together with external calibrators and internal control samples corresponding to at least 8% of the patient samples. The quantification ranges for isoniazid and acetyl isoniazid were 0.14-20 and 0.18-27 mg/L, respectively, for rifampicin 0.05-100 mg/L, for pyrazinamide 1-150 mg/L and for ethambutol 0.1-12 mg/L. In all aspects, the bioanalysis followed the Swedish national accredited standard according to ISO 15189. Release of results was based on internal control sample performance by applying a limited set of Westgard rules. The analytical accuracy and precision [coefficient of variation (CV%)] was 1.2% and 8.2% for rifampicin, #1.6% and 12% for isoniazid, 0.62% and 12% for pyrazinamide and 3.1% and 9% for ethambutol, respectively. The free drug concentrations for rifampicin, pyrazinamide and ethambutol were calculated using previously reported protein bindings of 80%, 10% and 20%, respectively, whereas isoniazid was regarded as unbound according to the literature and the free fraction was measured.
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Statistical analysis
Continuous data are presented as median and IQR. Comparison of groups was performed with the Mann-Whitney U-test for continuous variables and the v 2 test or Fisher's exact test for categorical variables (Dell Statistica software version 13, Tulsa, OK, USA). A P value of ,0.05 was considered as statistically significant. For each patient, the highest concentration of each drug measured at pre-dose and at 2, 4 or 6 h at week 2 was defined as C high . The lower limits of the current range for peak plasma concentrations used in clinical practice [rifampicin (8 mg/L), isoniazid (3 mg/L), pyrazinamide (35 mg/L) and ethambutol (2 mg/L)] were applied to classify whether individual C high levels were below recommended ranges. 4, 37 The area under the free concentration versus time profile from 0 to 6 h (ƒAUC 0-6 ) was estimated by using non-compartmental analysis and the linear trapezoidal method for total concentrations as well as by correcting for protein binding. 38 The acetylator phenotype (slow versus fast) for each subject was calculated using the metabolic ratio of acetyl isoniazid concentration to isoniazid concentration at 4 h post-dose at week 2 as previously described, which corresponds to the arylamine N-acetyltransferase 2 (NAT2) genotype. 39 A statistical method including random and fixed effects (with patient as random effect) was used to compare mean drug concentration 
Results
Patient characteristics
Among 112 adult patients eligible for inclusion, 38 patients were recruited, of whom 31 were analysed. The 74 patients not recruited to the study did not differ significantly from the study participants with regard to age or gender (data not shown). The primary reason for non-participation was initiation of treatment before inclusion was possible (n " 58). Seven patients were excluded due to diagnoses other than TB (n " 3), withdrawal from the study (n " 1) or adverse events (n " 3). An additional 16 patients declined or could not adhere to the study protocol. Patient characteristics are listed in Table 1 . The median age was 33 years (IQR 26-44 years). Nearly two-thirds of the patients were females (61%, 19/31) and 61% originated from sub-Saharan Africa. Comorbidities contributing to the Charlson comorbidity index 40 were infrequent (3/31, 10%) and no patient had HIV. One patient had documented alcohol abuse. Bacteriologically confirmed TB was present in 84% (26/31) of the patients, whereas the remaining patients had clinically diagnosed TB. Among PTB patients at baseline, 21% (5/24) had cavity/cavities on chest X-ray, 25% (6/24) were sputum smear positive and 83% (20/24) were sputum culture positive. Treatment success according to WHO criteria was 100% (31/31) and the overall proportion of relapse-free cure was 94% (29/31).
First-line drug concentrations in relation to TB manifestation, disease activity and individual fluctuations
Lower than recommended concentrations of rifampicin at week 2 were detected in 42% (13/31) of the patients, whereas 19% (6/31), 27% (7/26) and 16% (3/19) had low concentrations of isoniazid, pyrazinamide and ethambutol, respectively. Distributions of C high for the first-line drugs are shown in Figure 1 and PK profiles at week 2 are shown in Figure S1(a-d) . There was no difference in the median dose per kg of bodyweight administered to patients with low versus normal C high of the first-line drugs (9.9 versus 9.2 mg/kg for rifampicin, 5.0 versus 5.0 mg/kg for isoniazid and 25.3 versus 25.1 mg/kg for pyrazinamide) except ethambutol where there was a lower median dose given (15.8 versus 20.0 mg/kg) in patients with low (3/19 patients with available data) versus normal C high for ethambutol.
The 2 h blood sample at week 2 was available for all patients, whereas for seven patients either the 4 h or the 6 h blood sample was missing. The C high of isoniazid corresponded to the sample obtained 2 h after drug intake in all patients and for rifampicin in 84% (26/31) of the patients. For pyrazinamide and ethambutol, the C high was obtained at 2-3 h after drug intake for 65% (17/26) and 89% (17/19), respectively.
The median C high of rifampicin at week 2 was significantly lower in PTB patients than in the EPTB group, whereas this difference was not observed for isoniazid (Table 1) . It is noteworthy that six out of seven patients in the EPTB group were women. In another exploratory analysis, plasma C high values of rifampicin below the currently lowest recommended concentration in clinical routine (8 mg/L) were more common in PTB patients (P " 0.013, n " 31) and associated with lower levels of isoniazid The majority of patients with available drug concentration data for isoniazid from at least two different timepoints (week 2, 4 or 12) showed little variability across the lower recommended drug concentration (83%, 20/24), whereas rifampicin concentrations showed greater variability at these timepoints (61%, 14/23). When considering patients with drug concentrations available 2 h after drug intake at weeks 2, 4 and 12 without any dose adjustments, rifampicin concentrations showed significantly higher individual fluctuations compared with isoniazid levels (P , 0.001; Figure 2 ). Fast acetylators had significantly lower isoniazid median C high at week 2 compared with slow acetylators [3.2 (n " 11) versus 6.2 mg/L (n " 16), P " 0.002] and likewise at week 4 and week 12 ( Figure S2 ).
Exploratory analysis of C high , ƒC high , AUC 0-6 and ƒAUC 0-6 of first-line TB drugs in relation to the MIC Individual MIC values for MGIT were in agreement with the MYCOTB method within +1 2-fold MIC dilution step in .95% of the observations (Table S1) . No isolates showed with high 
Discussion
In our study of patients on standard treatment for drugsusceptible TB in a low endemic setting, low drug concentrations of the first-line drugs were common, especially for rifampicin (42% (a) Distribution of the C high /MIC for rifampicin (n " 26) and isoniazid (n " 25) at week 2 in patients with active TB. The median C high /MIC ratio for rifampicin was 164 and 128 for isoniazid. Calculated free (f) ranges of the C high /MIC ratio for rifampicin and isoniazid are presented in Table 2 . Free concentrations of isoniazid were measured and the drug is regarded as unbound in plasma based on literature estimates. (b) Distribution of C high /MIC for ethambutol (n " 16) and pyrazinamide (n " 21) at week 2 in patients with active TB. The median C high /MIC ratio for ethambutol was 2.5 and 1.3 for pyrazinamide. Calculated free (f) ranges of the C high /MIC ratio for ethambutol and pyrazinamide are presented in Table 3 . EMB, ethambutol; INH, isoniazid; PZA, pyrazinamide; RIF, rifampicin.
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of patients). Additionally, there was a wide distribution of the ratios between drug exposures and MICs (C high /MIC and AUC 0-6 /MIC). Our results are consistent with previous studies mostly from high endemic areas and confirm that rifampicin concentrations ,8 mg/L (with doses used in current clinical practice) are common, ranging from about 30% to 85%. 4, 6, 7 We also found significant individual fluctuations of rifampicin concentrations compared with isoniazid during the first 3 months of treatment, which needs to be taken into account when TDM is used in clinical practice. In agreement with previous findings, the level of isoniazid concentrations significantly correlated to the acetylator status. 41 Preclinical data have shown a dose-dependent bactericidal effect for rifampicin, 20, 22, 42, 43 which along with low exposures observed in clinical studies have inspired several clinical trials to investigate higher doses of rifampicin, including the HIGHRIF study, which included doses up to 40 mg/kg. 25, 27, 44 A model-based, pharmacometric approach on the same data showed a relationship between AUC and time to positivity in liquid culture. 45 The increase in efficacy for higher doses is complicated by the concentration-and time-dependent elimination as well as a dose dependency in bioavailability of rifampicin, 26 which needs to be accounted for using a model-based approach if rifampicin is to be monitored using TDM.
In a study of PTB patients in Peru, rifampicin doses ranging from 10 to 20 mg/L were used. 44 The median C max and AUC 0-6 on standard dosing of rifampicin were, respectively, 6.2 mg/L and 24.9 mgÁh/L compared with 10.0 mg/L (C high ) and 35 mgÁh/L in the present study in Sweden of both PTB and EPTB patients. In another study of PTB patients conducted in a high endemic area, the three most important predictors of a poor clinical outcome were pyrazinamide AUC 0-24 363 mgÁh/L, rifampicin AUC 0-24 13 mgÁh/L and isoniazid AUC 0-24 52 mgÁh/L. 1 For the first-line drugs pyrazinamide and ethambutol, less is known about PK/PD distributions in humans. The relatively low plasma levels of ethambutol together with a modest clinical efficacy has suggested that ethambutol may be of limited clinical value. 46, 47 However, recent data show that ethambutol accumulates in TB lesions of the lung, which implies that optimizing exposures is of clinical importance. 47 Pyrazinamide is a sterilizing drug and has been shown to be important for a successful treatment outcome. 46 In a previous study, pyrazinamide plasma C max levels ,58.3 mg/L correlated to a poor 2 month sputum culture conversion. 1 In our limited cohort, all but two patients who could be evaluated for sputum culture conversion at month 2 (n " 14) had pyrazinamide plasma levels ,58.3 mg/L, but only one patient remained culture positive at month 2.
We used TBscore II in an effort to objectively grade disease severity. Indeed, there was a significant difference between the mean TBscore II in the present study (1.1 points) and cohorts of patients with active TB in sub-Saharan Africa (4.6 and 3.6 points in Ethiopia and Guinea Bissau, respectively). 31 Interestingly, in an exploratory analysis, we found that patients with rifampicin concentrations ,8 mg/L had significantly higher TBscore II than patients with rifampicin concentrations .8 mg/L. TB disease severity may be one important factor to consider in future TDM studies.
There is a scarcity of studies comparing concentration of TB drugs in PTB and EPTB patients, although a paediatric study showed significantly lower concentrations of rifampicin in PTB patients compared with EPTB patients. 48 The reason for lower peak rifampicin concentrations in patients with PTB compared with patients with EPTB in our limited number of patients deserves further investigation. Table 2 .
Free concentrations of isoniazid were measured and the drug is regarded as unbound in plasma based on literature estimates. INH, isoniazid; RIF, rifampicin. Free drug concentrations of isoniazid were measured and the drug is regarded as unbound in plasma based on literature estimates. Plasma concentrations of first-line anti-TB drugs versus MICs
JAC
Our study has several limitations. Some of the study participants had culture-negative TB (5/31, 16%) and thus did not have a bacteriologically confirmed diagnosis. The peak concentrations of pyrazinamide and ethambutol could not be determined in a small proportion of patients, partly due to delayed administration of the drugs in one of the centres. The sparse sampling strategy precluded a refined evaluation of the individual C max and consequently we used C high instead. AUC 0-6 was estimated with non-compartmental analysis based on sparse sampling without PK/PD modelling and thus the linear trapezoidal model provides crude estimations and should be interpreted with caution. Further, data were too limited to predict either AUC during the entire dosing interval or AUC 0-6 for pyrazinamide and ethambutol. The estimated drug concentrations in plasma might not reflect the concentration at the site of infection, such as in cavitary lung disease, but are more easily accessible for monitoring. 49 The lack of a reference method for MIC determination is an obstacle for defining PK/PD targets, as the ratio is highly dependent on which MIC method is used. We used the WHO-endorsed BACTEC 960 MGIT method for MIC determination, which was also proposed as a reference method in a recent technical report although without experimental support. 29 The results were compared and confirmed by WGS analysis of established drug resistance mutations as well as MIC determination in the MYCOTB method, a susceptibility testing method not yet endorsed by WHO. The value of individual MICs to modify a dosing regimen has been questioned recently, stressing the technical variability of MIC determinations. 50 In that respect, the relatively low inter-assay variability of the MGIT method is a strength of our study.
In conclusion, we found low drug concentrations of first-line TB drugs in general and for rifampicin in particular. Furthermore, there was a wide distribution of ratios between drug exposures and MICs in TB patients from this low endemic setting. So far, there is an overall lack of established PK/PD targets for TB drugs predictive of clinical outcome. Further studies are needed in which drug exposure, clinical outcome and MICs according to a reference method are investigated.
